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Aim: It has been recently shown that the original BODE index has a high degree of correlation 
with two modified BODE indexes using maximal oxygen uptake expressed either as mL/min/kg 
(mBODE) or as the percentage predicted (mBODE%). In this study we investigated the agree-
ment between the two modified BODE indexes (mBODE and mBODE%) in patients with stable 
chronic obstructive pulmonary disease (COPD).
Methods: A total of 169 patients with stable COPD were enrolled in this cross-sectional study. 
Differences between the two mBODE indexes were assessed using kappa coefficients and 
Bland-Altman plots. One out of every three patients underwent the six-minute walking test to 
investigate the agreement with the original BODE index.
Results: Correlations between the two mBODE indexes with each other (r = 0.96, P  0.001) 
and with the original BODE index (mBODE r = 0.88, P  0.001; mBODE% r = 0.93, 
P  0.001) were excellent. However, the two mBODE indexes were significantly different 
from each other (mBODE 5.27 ± 2.3 versus mBODE% 4.31 ± 2.5; P  0.001). The kappa 
coefficients were significantly lower (entire study group k = 0.5, P  0.001) for every 
GOLD stage. The mean difference between the two mBODE indexes was 0.8 ± 0.6 units. 
Differences with the original BODE were higher for the mBODE (1.8 ± 0.9) than for the 
mBODE% (0.6 ± 0.8).
Conclusions: The new mBODE indexes are highly correlated but significantly different from 
each other. The differences between the novel indexes deserve further scrutiny.
Keywords: BODE index, chronic obstructive pulmonary disease, exercise testing, 
  multidimensional evaluation, oxygen uptake
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating lung 
disease characterized by irreversible airflow limitation in the lungs, which is predicted to 
have a trend of steadily increasing morbidity and mortality in the near future.1 In addition 
to causing inflammatory and structural changes in the lung resulting in alterations of ven-
tilatory mechanics2 and gas exchange,3 COPD may also have systemic manifestations,4 
such as impairment in nutritional status5 and peripheral muscle dysfunction.6 In this 
context, a multidimensional grading system that assesses the respiratory and systemic 
expressions of COPD is important for categorization and outcome prediction.
Celli et al7 have recently introduced the use of the BODE index, a multidimensional 
10-point scale assessing four prognostic factors in COPD patients, namely body mass 
index (B), degree of airflow obstruction (O), functional dyspnea (D), and exercise 
capacity (E) as assessed by the six-minute walk test (6MWT). The BODE index has International Journal of COPD 2010:5 134
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been extensively validated and shown to predict mortality7 
and future hospitalizations.8 In addition, it has been found 
to be a good predictor of exacerbations9 and health-related 
  quality of life.10
However, several modifications of the original BODE 
index have been proposed to obtain novel indexes that may 
be more accurate and easier to use.11,12 In this regard, the 
6MWT used in the original BODE index is a submaximal 
test, is dependent on individual motivation, and may not 
express the real physical capacity of the patient. Interest-
ingly, correlations with the maximal oxygen uptake (VO2max) 
are only moderate.13 In contrast, maximal cardiopulmonary 
exercise testing (CPET) is considered the gold standard to 
assess maximal exercise tolerance. In particular, VO2max is an 
objective measure of physical fitness and might serve as a 
physical training target,14 a predictor of survival rates,15 and 
a disability index for COPD patients.16 Of note, the original 
BODE index has been recently correlated with two modi-
fied BODE indexes replacing 6MWT with VO2max expressed 
either as the percentage of predicted values (mBODE%) or 
as absolute values in mL/min/kg (mBODE).17 Intriguingly, 
the modified BODE indexes have been recently linked to 
survival in COPD patients.18 In addition, a highly significant 
correlation between the original BODE and the modified 
indexes has been reported.17 It has been therefore suggested 
that the original BODE index is highly effective in the 
evaluation of COPD patients. Although valuable data have 
been presented – including the use of  VO2max in the BODE 
index – an analysis of the agreement between the two modi-
fied BODE indexes has not yet been performed. Therefore, 
the question as to whether these indexes may have the same 
properties remains open. The purpose of this study was to 
analyze the agreement between the two modified BODE 
indexes in a group of patients with stable COPD. We also 
sought to investigate the relation between the modified BODE 
indexes and the original BODE in a subsample of patients.
Materials and methods
This is an observational, cross-sectional, prospective study. 
All procedures were approved by the local Institution Review 
Board and written informed consent was obtained from all 
participants.
Subjects
A total of 169 COPD patients were included in the study. Study 
participants were recruited from our outpatient clinics during 
routine visits. Patients fulfilling the following inclusion crite-
ria were invited to participate in the study: a) being an adult 
patient diagnosed as having COPD according to international 
guidelines19 and b) being clinically stable during the previous 
three months. Exclusion criteria were: a) recent exacerbations 
(in the previous three months) requiring systemic corticoste-
roids or antibiotics,20 and b) any contraindication or inability 
to perform any of the study tests (uncontrolled heart disease, 
acute pulmonary disease, and other conditions).14 Medications 
already prescribed were continued during the study.
Patients underwent a complete clinical and functional 
evaluation followed by a maximal CPET on a cycle ergom-
eter. To be able to compare our findings with those achieved 
using the original BODE index, one out of every three 
patients performed the 6MWT according to international 
recommendations.21 Clinical and functional evaluation con-
sisted of dyspnea scoring, nutritional evaluation, spirometric 
testing, and arterial blood-gas analysis.
Measurements
Dyspnea
Basal dyspnea was assessed using the modified Medical 
Research Council (MRC) scale.22 This is a five-point scale 
based on degrees of various physical activities that precipi-
tate dyspnea.
Nutritional status
Nutritional status was assessed by calculating body mass 
index (BMI). BMI was obtained by dividing body weight in 
kilograms by height in square meters (kg/m2). A BMI of less 
than 21.0 kg/m2 was considered to be underweight.7
Pulmonary function tests
Spirometric investigations were carried out on a pneumo-
tachograph spirograph Masterlab (Erich Jaeger GMBH, 
Wuerzburg, Germany), following American Thoracic 
Society (ATS) recommendations.23 For the purpose of this 
study, values of forced expiratory volume in one second 
(FEV1) were recorded. Blood-gas analyses were carried 
out with an ABL-700 analyser (Radiometer, Copenhagen, 
Denmark) using arterial blood samples taken from the radial 
or humeral artery at rest while the patient was breathing 
room air. Arterial oxygen partial pressure (PaO2) carbon 
dioxide partial pressure (PaCO2) and pH were recorded 
following the manufacturer’s instructions and in keeping 
with Spanish Society of Pulmonology and Thoracic Surgery 
recommendations.24
Maximal cardiopulmonary exercise test
Maximal CPET was performed on a cycle ergometer (Collins 
Respiratory; ErgoMed, Seattle, WA, USA). Maximal exercise 
  tolerance was measured by a symptom-limited graded International Journal of COPD 2010:5 135
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exercise test performed while the patient was breathing room 
air. Breathing was continuously monitored, and inhaled and 
exhaled gases were collected. We determined the VO2peak and 
carbon dioxide production, an indirect measure of anaerobic 
threshold. VO2peak was expressed as an absolute value or as a 
percentage of the predicted value (in mL/min/kg). An average 
of the last 20 seconds of each minute was used for the pur-
pose of analysis. The respiratory pattern (maximal breathing 
capacity, tidal volume, respiratory rate) during exercise was 
carefully recorded. Electrocardiogram and pulse oxymetry 
monitoring were performed during exercise. Data for venti-
lation and gas analysis were instantly obtained and analyzed 
breath-by-breath by a computer connected with the cycle 
ergometer. Oxygen was measured by a zirconia cell and carbon 
dioxide by an infrared cell. Patients were monitored for three 
minutes at rest and then began to pedal without any resistance 
for one minute. The level of resistance was then increased by 
10–15 watts every minute until the maximal exercise level 
was reached. After exercise, we assessed heart rate and blood 
pressure. Dyspnea, leg fatigue, and chest pain were assessed 
after exercise according to a modified Borg’s scale.25
Six-minute walking test
The 6MWT was performed a few days before CPET follow-
ing the current recommendations.21 Prior to the index test, 
a trial test was performed to avoid a training effect.
Modified BODE Indexes
The two mBODE indexes were calculated using BMI, FEV1, 
and MRC as in the original index.7 However, the use of 
6MWT was replaced with VO2peak values, expressed either 
in mL/min/kg (mBODE) or as the percentage of predicted 
(mBODE%). Each variable was rated on a four-point (0–3) 
scale, the only exception being BMI, which was coded as a 
dichotomous variable (0 or 1). mBODE indexes were calcu-
lated as the sum score ranging from 1 to 10. The scale was then 
divided into quartiles, with the first quartile corresponding 
to scores of 0–2 points, the second quartile to scores of 3–4 
points, the third quartile to scores of 5–6 points, and the fourth 
quartile to scores of 7–10 points.7 Although several different 
stratifications may be theoretically used, VO2peak values were 
stratified as proposed by Cardoso et al,17 to make results com-
parable. The values of VO2peak in mL/min/kg were therefore 
stratified according to previous methodology26 as follows: 
score 0  25 mL/min/kg; score 1 = 20–25 mL/min/kg; 
score 2 = 15–20 mL/min/kg; score 3  15 mL/min/kg. 
Similarly, values of  VO%2peak predicted were stratified27 
as follows: score 0  70%pred; score 1 = 60%–69%pred; 
score 2 = 40%–59%pred; score 3  40%pred.
Statistical analysis
Statistical analysis was performed using the Statistical 
Package for Social Sciences (version 15.0; SPSS Inc., 
Chicago, IL, USA), Qualitative variables are expressed as 
absolute and relative frequencies. Quantitative variables are 
expressed as means and standard deviations. For descriptive 
purposes, variables are presented for the entire study cohort 
and according to GOLD stages.19 GOLD stages I and II were 
unified within one group since only eight patients had Stage I 
disease. Comparisons between qualitative variables were 
performed using the χ2 test or the Fisher’s exact test.
Correlations were analyzed by calculating the Pearson’s 
correlation coefficient (r). Comparisons of quantitative vari-
ables were performed using the Student’s t test. Differences 
across different GOLD stages were assessed using analysis 
of variance (ANOVA). Agreement between the mBODE 
and mBODE% was studied using the kappa coefficient 
(k) according to the quartiles of the two mBODE indexes. 
The degree of agreement was also investigated using the 
Bland–Altman plot (difference versus average). In this 
method, the mean differences between measures are reported 
as means ±2 standard deviations in parentheses.28 The alpha 
error was set at 0.05.
Results
Comparison between modified  
BODE indexes
The clinical and functional characteristics of the 169 partici-
pants are shown in Table 1. Correlations between the two 
mBODE indexes and the corresponding VO2peak value were 
good (mBODE index: r = -0.68, P  0.001; mBODE% 
index: r = -0.75, P  0.001). The correlation between the 
two mBODE indexes was excellent (r = 0.96, P  0.001, 
  Figure 1). However, the two mBODE indexes were signifi-
cantly different from each other (Table 1). These differences 
were evident for the entire cohort (P  0.001) and throughout 
all GOLD stages (P  0.001 for all stages, Table 1).
Kappa coefficients were significantly low in the entire 
study cohort (k = 0.5, P  0.001), but improved in patients 
with advanced GOLD stages (GOLD I–II: k = 0.49, 
P  0.001; GOLD III: k = 0.3, P  0.001; GOLD IV:   
k = 0.69, P  0.001).
Bland–Altman plots are presented in Figure 2. In the 
entire study cohort, the mean difference between the two 
mBODE indexes was 0.95 (-0.46–2.37) units. The mean 
differences according to GOLD stages were as follows: 
GOLD I–II: 1.1 (-0.4–2.63); GOLD III: 1 (-0.35–2.35), 
and GOLD IV: 0.7 (-0.5–1.98) units.International Journal of COPD 2010:5 136
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Table 1 Clinical and functional characteristics of the 169 study participants
Characteristics Cohort (n = 169) GOLD I–II (n = 63) GOLD III (n = 53) GOLD IV (n = 53) P value*
Males 165 (97.6%) 62 (98.4%) 50 (94.3%) 53 (100%) NS
Age (years) 64 ± 7 63 ± 6 64 ± 7 64 ± 7 NS
Dyspnea (MRC) 2.12 ± 1.2 1.52 ± 1.1 2.3 ± 0.9 2.6 ± 1.2 0.001
BMI (kg/m2) 28.6 ± 5.09 28.9 ± 4.6 28.9 ± 4.6 27.8 ± 5.9 NS
FVC (%) 81.6 ± 17.9 94.9 ± 14.9 77.1 ± 13.2 70.07 ± 14.8 0.001
FEV1 (%) 46.2 ± 17.4 64.1 ± 12 40.5 ± 5.9 30.5 ± 10.3 0.001
FEV1/FVC (%) 44.4 ± 11.02 53.6 ± 7.8 41.7 ± 7.7 35.7 ± 8.5 0.001
pH 7.40 ± 0.03 7.41 ± 0.03 7.39 ± 0.02 7.40 ± 0.03 NS
PaCO2 42.5 ± 5.9 39.6 ± 3.6 42.3 ± 4.7 45.8 ± 7.4 0.001
PaO2 70.5 ± 10.4 75.3 ± 6.6 74.1 ± 7.9 61.7 ± 10.4 0.001
CPET power (watts) 63.7 ± 32.4 86.6 ± 32.4 59.4 ± 23.1 40.7 ± 20.4 0.001
VO2max (mL/min/kg) 16 ± 4.9 18.7 ± 4.5 15.2 ± 4.3 13.5 ± 4.3 0.001
VO2max (%) 61.8 ± 19.1 72.9 ± 18.1 58.9 ± 17.1 51.4 ± 15.1 0.001
mBODE 5.27 ± 2.3 3.1 ± 1.6 5.9 ± 1.4 7.5 ± 1.7 0.001
mBODE% 4.31 ± 2.5 2.02 ± 1.8 4.9 ± 1.5 6.4 ± 1.9 0.001
*Calculated by ANOVA with the exception of gender analysis (χ2 test). Data are expressed as means and standard deviations.
Abbreviations: NS, not significant; MRC, Medical Research Council scale; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; 
PaCO2, arterial carbon dioxide partial pressure; PaO2, arterial oxygen partial pressure; CPET, cardiopulmonary exercise test;   VO2max, maximal oxygen uptake.
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Figure 1 Scattergram and regression line showing a highly significant correlation 
between the two modified BODE indexes (r = 0.96, P  0.001). 
Comparison of mBODE indexes 
with original BODE
In order to compare the mBODE indexes with the 
original BODE index, a subgroup of 54 patients (Table 
2) performed the 6MWT (mean distance 517 ± 118 
metres). There was a high correlation between original 
BODE and both the mBODE (r = 0.88; P  0.001) and 
mBODE% (r = 0.93; P  0.001) indexes (Figure 3). 
Kappa coefficients were low for both mBODE-BODE 
(k = 0.12; P  0.001) and mBODE%-BODE (k = 
0.38; P  0.001). The agreement between the indexes 
was investigated using the Bland–Altman analysis. 
Results showed a mean difference in BODE points of 
1.8 (0.03–3.77) for mBODE and 0.6 (-1.1–2.32) for 
mBODE% (Figure 4).
Discussion
The present study demonstrates that the new modified BODE 
indexes are significantly different from each other with a 
mean difference of around 1 BODE point. These differences 
were less pronounced in the advanced stages of the disease, 
in which they were characterized by better agreement. 
Moreover, the agreement with the original BODE index was 
overall weak, and significantly lower for the mBODE than 
for the mBODE%.
The original BODE index is a simple multidimensional 
grading system which is superior to FEV1 alone for prediction 
of mortality and hospitalization rates among COPD patients. 
Since its first publication in 20047 this index has been exten-
sively used in different settings including pulmonary rehabili-
tation29 and lung volume reduction surgery.30 Several attempts 
have recently been made to improve the original BODE 
index, either by replacing or adding new components.11,12 
In our study, two novel mBODE indexes were constructed 
by replacing 6MWT with VO2peak expressed either as the International Journal of COPD 2010:5 137
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Figure 2 Bland-Altman plots exploring the differences between the two modified BODE indexes in A) the entire study cohort, as well as in B) patients with GOLD I–II, C) 
GOLD III, and D) GOLD IV. Mean differences: entire cohort: 0.95 (-0.46–2.37); GOLD I–II: 1.1 (-0.41–2.63), GOLD III: 1 (-0.35–2.35), and GOLD IV: 0.7 (-0.5 –1.98) units.
percentage of predicted values (mBODE%) or as the absolute 
values in mL/min/kg (mBODE). Although the novel indexes 
thus far have not been studied in detail, preliminary evidence 
has indicated that the mBODE% and the original BODE 
index show similar prognostic properties.18
The identification of novel diagnostic tools is an important 
clinical goal. Novel diagnostic tools or multicomponent mea-
sures are frequently being developed to improve prognostic 
models and to identify novel therapeutic targets for patients 
with COPD. In this context, novel assessment tools need to 
be validated prospectively against pre-existing methodolo-
gies. Two previous studies have investigated and validated the 
novel mBODE indexes.17,18 To this end, a feasible approach 
is simple linear regression analysis, as previously done by 
Cardoso et al.17 These authors have previously demonstrated 
a highly significant correlation between the original BODE 
index and the two mBODE indexes. Interestingly, in our study 
we were able to replicate these findings. However, it should be 
noted that the correlation between the original BODE index 
and VO2max was only moderate.17 It is well known that good 
correlation does not necessarily imply good agreement and 
vice versa.28 Therefore, the agreement between both indexes 
should be carefully evaluated by means of sound statisti-
cal analysis. The second report18 was a validation study of 
mBODE% suggesting that this instrument has a good abil-
ity to predict mortality in a similar manner as the original 
BODE. However, the authors found a difference of 1.4 points 
between the mBODE% and the original BODE. The study International Journal of COPD 2010:5 138
Lopez-Campos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
our study was not of prospective design and is therefore not 
suitable to confirm previous findings.
In our study, the two mBODE indexes showed a low 
degree of agreement, despite a high degree of correlation. 
Interestingly, kappa coefficients were low for the entire 
study cohort and in all GOLD stages, improving in advanced 
stages. Hence, a Bland–Altman plot of difference versus 
mean values showed a difference of about 1 point among the 
two mBODE indexes, which have proven to be a clinically 
relevant prognostic difference.31
Two findings of our study merit consideration. Firstly, 
patients in advanced stages of COPD had a higher degree 
of agreement. It is widely recognized that patients with 
advanced COPD suffer from severe impairment of functional 
capacity.32 In addition, the limitation in exercise capacity 
shows a lower variability in advanced stages characterized 
by a progressive reduction in the standard deviations of 
exercise variables (see Table 1).32 Secondly, the degree of 
agreement with the original BODE was different for the two 
mBODE indexes. Interestingly, the VO2peak is the only variable 
that differs between the two parameters. VO2peak is currently 
considered to be the best index of aerobic capacity and the 
gold standard for cardiorespiratory fitness. It represents the 
maximal achievable level of oxidative metabolism in large 
muscle groups.14 VO2peak is generally expressed as oxygen 
uptake in absolute units. However, VO2peak can be normal-
ized for body weight to compare VO2peak among subjects 
with different anthropometric measures.33,34 Of note, VO2peak 
may be expressed in normalized and absolute units,35 and the 
two different modalities may express complementary facets 
Table 2 Clinical and functional characteristics of participants 
performing the six-minute walking test
Characteristic Entire cohort (n = 54)
Males 51 (94.4%)
Age (years) 63 ± 7
Dyspnea (MRC) 1.09 ± 0.7
BMI (kg/m2) 28.8 ± 5.4
FVC (%) 90.7 ± 18.3
FEV1 (%) 58.4 ± 19
FEV1/FVC (%) 49.9 ± 10.8
pH 7.42 ± 0.03
PaCO2 40.6 ± 5,5
PaO2 71 ± 9.7
CPET power (watts) 84.5 ± 36
VO2max (mL/min/kg) 17.3 ± 5.5
VO2max (%) 71.4 ± 20.9
Six-minute walking test (metres) 517 ± 118
Data are expressed as means and standard deviations.
Abbreviations: MRC, Medical Research Council scale; BMI, body mass index; FVC, 
forced vital capacity; FEV1, forced expiratory volume in one second; PaCO2, arterial 
carbon dioxide partial pressure; PaO2, arterial oxygen partial pressure; CPET, cardio-
pulmonary exercise test;   VO2max, maximal oxygen uptake.
did not focus on the degree of agreement between the two 
measures. The present report expands previous studies on 
the mBODE indexes by analyzing the degree of agreement 
between each other using the kappa and Bland-Altman 
plots.28 Future longitudinal studies are needed to investigate 
whether the two new mBODE indexes differ in their ability 
to predict mortality or exacerbations in patients with COPD. 
Although this issue has been partly addressed in the past,18 
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Figure 3 Scattergram and regression line showing a highly significant correlation between the original BODE and A) mBODE (r = 0.88; P  0.001), as well as B) the mBODE% 
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Figure 4 Bland–Altman plots exploring the differences between the original BODE and A) mBODE, mean difference 1.8 (0.03–3.77), as well as B) the mBODE%, mean dif-
ference 0.6 (-1.1–2.32).
of aerobic capacity. It is possible that the use of different 
thresholds to stratify VO2peak values could yield different 
results regarding correlation and agreement. This may also 
explain the differences in agreement observed between 
the original BODE and the mBODE% compared with the 
mBODE. However, in this study we used the same thresh-
olds proposed by Cardoso et al17 to ensure comparability. 
Future studies should investigate the optimal cut-off values 
for VO2peak.
One difference between the present study and that of Car-
doso et al17 relies in the use of a cycle ergometer for VO2peak 
stratification instead of a treadmill. It is widely recognized 
that both methods have some differences. Maximal oxygen 
uptake is reported to be, on average, 5%–10% higher on a 
treadmill than on a cycle ergometer. Since some abnormali-
ties may occur only at the highest metabolic demand, the 
exact determination of VO2max in clinical practice is critical.14 
It should be noted, however, that both methods have been 
validated for COPD patients, with no clear difference 
between the two forms of exercise.36
Conclusions
In summary, our study suggests that the novel mBODE indexes 
are highly correlated, but significantly different from each 
other (mean difference of approximately 1 BODE point) as 
well as from the original BODE index. Taken together, our 
data reinforce the idea that the original BODE index is useful 
in clinical characterization of COPD patients. Nonetheless, 
the differences between the two novel indexes deserve further 
scrutiny.International Journal of COPD 2010:5
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